193 related articles for article (PubMed ID: 28923856)
1. Genomic Activation of
Goldstein JT; Berger AC; Shih J; Duke FF; Furst L; Kwiatkowski DJ; Cherniack AD; Meyerson M; Strathdee CA
Cancer Res; 2017 Dec; 77(24):6987-6998. PubMed ID: 28923856
[TBL] [Abstract][Full Text] [Related]
2. Role of peroxisome proliferator activated receptor-gamma in bacillus Calmette-Guérin bladder cancer therapy.
Langle Y; Lodillinsky C; Belgorosky D; Sandes EO; Eiján AM
J Urol; 2012 Dec; 188(6):2384-90. PubMed ID: 23088980
[TBL] [Abstract][Full Text] [Related]
3. Cell-Intrinsic Tumorigenic Functions of PPARγ in Bladder Urothelial Carcinoma.
Sanchez DJ; Missiaen R; Skuli N; Steger DJ; Simon MC
Mol Cancer Res; 2021 Apr; 19(4):598-611. PubMed ID: 33431608
[TBL] [Abstract][Full Text] [Related]
4. Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer.
Korpal M; Puyang X; Jeremy Wu Z; Seiler R; Furman C; Oo HZ; Seiler M; Irwin S; Subramanian V; Julie Joshi J; Wang CK; Rimkunas V; Tortora D; Yang H; Kumar N; Kuznetsov G; Matijevic M; Chow J; Kumar P; Zou J; Feala J; Corson L; Henry R; Selvaraj A; Davis A; Bloudoff K; Douglas J; Kiss B; Roberts M; Fazli L; Black PC; Fekkes P; Smith PG; Warmuth M; Yu L; Hao MH; Larsen N; Daugaard M; Zhu P
Nat Commun; 2017 Jul; 8(1):103. PubMed ID: 28740126
[TBL] [Abstract][Full Text] [Related]
5. Recurrent activating mutations of PPARγ associated with luminal bladder tumors.
Rochel N; Krucker C; Coutos-Thévenot L; Osz J; Zhang R; Guyon E; Zita W; Vanthong S; Hernandez OA; Bourguet M; Badawy KA; Dufour F; Peluso-Iltis C; Heckler-Beji S; Dejaegere A; Kamoun A; de Reyniès A; Neuzillet Y; Rebouissou S; Béraud C; Lang H; Massfelder T; Allory Y; Cianférani S; Stote RH; Radvanyi F; Bernard-Pierrot I
Nat Commun; 2019 Jan; 10(1):253. PubMed ID: 30651555
[TBL] [Abstract][Full Text] [Related]
6. Distinct gene regulatory programs define the inhibitory effects of liver X receptors and PPARG on cancer cell proliferation.
Savic D; Ramaker RC; Roberts BS; Dean EC; Burwell TC; Meadows SK; Cooper SJ; Garabedian MJ; Gertz J; Myers RM
Genome Med; 2016 Jul; 8(1):74. PubMed ID: 27401066
[TBL] [Abstract][Full Text] [Related]
7. Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems.
Eriksson P; Aine M; Veerla S; Liedberg F; Sjödahl G; Höglund M
BMC Med Genomics; 2015 May; 8():25. PubMed ID: 26008846
[TBL] [Abstract][Full Text] [Related]
8. Pparg promotes differentiation and regulates mitochondrial gene expression in bladder epithelial cells.
Liu C; Tate T; Batourina E; Truschel ST; Potter S; Adam M; Xiang T; Picard M; Reiley M; Schneider K; Tamargo M; Lu C; Chen X; He J; Kim H; Mendelsohn CL
Nat Commun; 2019 Oct; 10(1):4589. PubMed ID: 31597917
[TBL] [Abstract][Full Text] [Related]
9. Bladder-cancer-associated mutations in
Halstead AM; Kapadia CD; Bolzenius J; Chu CE; Schriefer A; Wartman LD; Bowman GR; Arora VK
Elife; 2017 Nov; 6():. PubMed ID: 29143738
[TBL] [Abstract][Full Text] [Related]
10. Higher expression of peroxisome proliferator-activated receptor γ or its activation by agonist thiazolidinedione-rosiglitazone promotes bladder cancer cell migration and invasion.
Yang DR; Lin SJ; Ding XF; Miyamoto H; Messing E; Li LQ; Wang N; Chang C
Urology; 2013 May; 81(5):1109.e1-6. PubMed ID: 23522297
[TBL] [Abstract][Full Text] [Related]
11. Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes.
Biton A; Bernard-Pierrot I; Lou Y; Krucker C; Chapeaublanc E; Rubio-Pérez C; López-Bigas N; Kamoun A; Neuzillet Y; Gestraud P; Grieco L; Rebouissou S; de Reyniès A; Benhamou S; Lebret T; Southgate J; Barillot E; Allory Y; Zinovyev A; Radvanyi F
Cell Rep; 2014 Nov; 9(4):1235-45. PubMed ID: 25456126
[TBL] [Abstract][Full Text] [Related]
12. Using Copy Number Alterations to Identify New Therapeutic Targets for Bladder Carcinoma.
Conconi D; Sala E; Bovo G; Strada G; Dalprà L; Lavitrano M; Bentivegna A
Int J Mol Sci; 2016 Feb; 17(3):271. PubMed ID: 26927059
[TBL] [Abstract][Full Text] [Related]
13. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype.
Rebouissou S; Bernard-Pierrot I; de Reyniès A; Lepage ML; Krucker C; Chapeaublanc E; Hérault A; Kamoun A; Caillault A; Letouzé E; Elarouci N; Neuzillet Y; Denoux Y; Molinié V; Vordos D; Laplanche A; Maillé P; Soyeux P; Ofualuka K; Reyal F; Biton A; Sibony M; Paoletti X; Southgate J; Benhamou S; Lebret T; Allory Y; Radvanyi F
Sci Transl Med; 2014 Jul; 6(244):244ra91. PubMed ID: 25009231
[TBL] [Abstract][Full Text] [Related]
14. Bacillus Calmette-Guérin induces the expression of peroxisome proliferator-activated receptor gamma in bladder cancer cells.
Lodillinsky C; Umerez MS; Jasnis MA; Casabé A; Sandes E; Eiján AM
Int J Mol Med; 2006 Feb; 17(2):269-73. PubMed ID: 16391825
[TBL] [Abstract][Full Text] [Related]
15. The peroxisome proliferator-activated receptor gamma regulates trophoblast cell differentiation in mink (Mustela vison).
Desmarais JA; Lopes FL; Zhang H; Das SK; Murphy BD
Biol Reprod; 2007 Nov; 77(5):829-39. PubMed ID: 17615406
[TBL] [Abstract][Full Text] [Related]
16. Pparg signaling controls bladder cancer subtype and immune exclusion.
Tate T; Xiang T; Wobker SE; Zhou M; Chen X; Kim H; Batourina E; Lin CS; Kim WY; Lu C; Mckiernan JM; Mendelsohn CL
Nat Commun; 2021 Oct; 12(1):6160. PubMed ID: 34697317
[TBL] [Abstract][Full Text] [Related]
17. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
Lüdtke A; Buettner J; Schmidt HH; Worman HJ
J Med Genet; 2007 Sep; 44(9):e88. PubMed ID: 17766367
[TBL] [Abstract][Full Text] [Related]
18. Identification of a three-gene expression signature of early recurrence in non-muscle-invasive urothelial cell carcinoma of the bladder.
Dubosq F; Ploussard G; Soliman H; Turpin E; Latil A; Desgrandchamps F; de The H; Mongiat-Artus P
Urol Oncol; 2012; 30(6):833-40. PubMed ID: 21489836
[TBL] [Abstract][Full Text] [Related]
19. Activation of PPARγ suppresses proliferation and induces apoptosis of esophageal cancer cells by inhibiting TLR4-dependent MAPK pathway.
Wu K; Yang Y; Liu D; Qi Y; Zhang C; Zhao J; Zhao S
Oncotarget; 2016 Jul; 7(28):44572-44582. PubMed ID: 27323819
[TBL] [Abstract][Full Text] [Related]
20. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.
Guo CC; Dadhania V; Zhang L; Majewski T; Bondaruk J; Sykulski M; Wronowska W; Gambin A; Wang Y; Zhang S; Fuentes-Mattei E; Kamat AM; Dinney C; Siefker-Radtke A; Choi W; Baggerly KA; McConkey D; Weinstein JN; Czerniak B
Eur Urol; 2016 Oct; 70(4):611-620. PubMed ID: 26988609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
